Xencor, Inc Increase (Decrease) in Contract with Customer, Asset
Xencor, Inc (XNCR) reported Increase (Decrease) in Contract with Customer, Asset of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2023-02-27
- Xencor, Inc increase (decrease) in contract with customer, asset for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc increase (decrease) in contract with customer, asset for the quarter ending 2021-09-30 was -$121.00K.
- Xencor, Inc increase (decrease) in contract with customer, asset for the quarter ending 2021-06-30 was -$12.00M.
- Xencor, Inc increase (decrease) in contract with customer, asset for the quarter ending 2021-03-31 was $62.00K.
- Xencor, Inc increase (decrease) in contract with customer, asset for fiscal 2022 was $0.00.
- Xencor, Inc increase (decrease) in contract with customer, asset for fiscal 2021 was -$12.06M, a 197.24% decline from fiscal 2020.
- Xencor, Inc increase (decrease) in contract with customer, asset for fiscal 2020 was $12.40M.
- Xencor, Inc increase (decrease) in contract with customer, asset for fiscal 2018 was $46.00K.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$121.00K derived: sum of 2 quarters · filed 2023-02-27 | -$12.12M derived: sum of 3 quarters · filed 2023-02-27 | -$12.06M 10-K · filed 2023-02-27 |
| 2021-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$12.12M derived: sum of 2 quarters · filed 2021-11-08 | -$12.06M 10-Q · filed 2021-11-08 | $395.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$11.94M 10-Q · filed 2021-08-04 | $516.00K derived: sum of 3 quarters · filed 2023-02-27 | |
| 2021-03-31 | $62.00K 10-Q · filed 2021-05-05 | $12.52M derived: sum of 2 quarters · filed 2023-02-27 | ||
| 2020-12-31 | $12.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $12.40M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | -$53.00K 10-Q · filed 2021-11-08 | |||
| 2019-09-30 | $15.00M 10-Q · filed 2020-11-06 | |||
| 2018-12-31 | $46.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |